However, some in vitro studies have demonstrated that genistein, at low doses (2 μM, 24 h) and in the presence of a synthetic androgen, may have a stimulating effect on the expression of AR pathway-related genes (PSA, KLK4, NKX3.1, STAMP2) in metastatic prostate cancer cells (Lazarevic et al., 2008[76]) (Figure 1(Fig. 1)). Here, KLK3 is linked to metastatic prostate carcinoma.